Paul Tudor Jones Aclaris Therapeutics, Inc. Transaction History

Tudor Investment Corp Et Al

$26.8 Billion
Q3 2024

A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 33,183 shares of ACRS stock, worth $68,025. This represents 0.0% of its overall portfolio holdings.

Number of Shares

33,183

Previous 33,183 -0.0%

Holding current value

$68,025

Previous $36,000 2.78%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	BUY	$6.56 - $10.95 $6 - $10	1 Added 0.0%	33,183 $227,000
Q2 2023 Aug 14, 2023	BUY	$7.89 - $10.64 $16,079 - $21,684	2,038 Added 6.54%	33,182 $344,000
Q1 2023 May 15, 2023	BUY	$7.07 - $17.95 $220,188 - $559,034	31,144 New	31,144 $252,000
Q2 2022 Aug 15, 2022	BUY	$10.16 - $17.08 $122,834 - $206,497	12,090 New	12,090 $169,000
Q4 2021 Feb 14, 2022	SELL	$12.27 - $18.49 $129,313 - $194,866	-10,539 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$13.38 - $18.8 $141,011 - $198,133	10,539 New	10,539 $190,000
Q4 2020 Feb 16, 2021	SELL	$2.65 - $7.61 $54,987 - $157,907	-20,750 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$1.5 - $2.71 $56,964 - $102,914	-37,976 Reduced 64.67%	20,750 $53,000
Q1 2020 May 15, 2020	SELL	$0.75 - $2.18 $150 - $436	-200 Reduced 0.34%	58,726 $61,000
Q3 2019 Nov 14, 2019	BUY	$0.79 - $2.47 $46,551 - $145,547	58,926 New	58,926 $64,000
Q1 2019 May 15, 2019	SELL	$5.63 - $7.84 $72,660 - $101,183	-12,906 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$6.3 - $15.4 $81,307 - $198,752	12,906 New	12,906 $95,000
Q1 2018 May 15, 2018	SELL	$17.08 - $25.64 $210,015 - $315,269	-12,296 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$21.47 - $27.8 $263,995 - $341,828	12,296	12,296 $303,000

Others Institutions Holding ACRS

# of Institutions

Shares Held

50.7M

Call Options Held

30.6K

Put Options Held

View Full List

About Aclaris Therapeutics, Inc.

Ticker ACRS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 66,671,800
Market Cap $137M
Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...

More about ACRS

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account